China’s National Development & Reform Commission (“NDRC”) announced this week that it has fined two domestic pharmaceutical companies for monopolizing bulk sales of promethazine hydrochloride in violation of the country’s Anti-Monopoly Law (“AML”). The decision, NDRC’s first AML action in the life sciences sector since the law went into effect in 2008, follows last week’s public confirmation by the agency of a significant antitrust investigation of Chinese state-owned companies, also the first of its kind. These announcements indicate that NDRC is becoming more active in its enforcement of the AML’s provisions regarding monopolistic conduct.
Share on
|
|
The Chinese National Development & Reform Commission fines two pharmaceutical companies for abusing dominant position (Shandong Weifang Shuntong Pharmaceutical / Weifang Huaxin Medicine Trade)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
